 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || betamethasone (SURF-201) / Harrow Health
Clinical, Surgery: 0.2% Betamethasone Sodium Phosphate: A Multicenter, Randomized, Double-Masked Study to Compare Its Ocular Safety, Tolerability, and Efficacy to Vehicle in Cataract Surgery Subjects. (Pubmed Central) - Aug 11, 2023
A slightly higher incidence of adverse events occurred in subjects in the SURF-201 treatment group (n=27/40 [67.5%]) compared to the vehicle treatment group (n=23/43 [53.5%]). SURF-201 is an effective topical, preservative-free corticosteroid when dosed BID for the treatment of postoperative inflammation and prevention of pain in a post-cataract population.
- ||| betamethasone (SURF-201) / Harrow Health
Trial completion, Trial completion date, Trial primary completion date, Adverse events, Surgery: Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects (clinicaltrials.gov) - Dec 29, 2020
P2, N=91, Completed, Sponsor: Surface Pharmaceuticals, Inc.
SURF-201 is an effective topical, preservative-free corticosteroid when dosed BID for the treatment of postoperative inflammation and prevention of pain in a post-cataract population. Recruiting --> Completed | Trial completion date: Jul 2020 --> Nov 2020 | Trial primary completion date: Jul 2020 --> Nov 2020
- | betamethasone (SURF-201) / Harrow Health
New P2 trial, Adverse events, Surgery: Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects (clinicaltrials.gov) - Mar 26, 2020
P2, N=80, Recruiting, Sponsor: Surface Pharmaceuticals, Inc.